Invenomic Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Invenomic Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-968,234	Closed	-$56.2M	–	176
2023 Q3	$56.2M	Buy	968,234 +414,551	+75%	+$25.4M	2.36%	5
2023 Q2	$35.4M	Sell	553,683 -21,802	-4%	-$1.46M	1.79%	14
2023 Q1	$39.9M	Buy	+575,485	New	+$40.6M	2.25%	9

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invenomic Capital Management's BMY Position: Q4 2023 in Review

Invenomic Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 968,234 shares — an estimated $56.2M sold.

Invenomic Capital Management first reported a position in BMY in Q1 2023 and held it in 3 quarters. The position peaked at $56.2M in Q3 2023. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Invenomic Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Invenomic Capital Management sold 968,234 Bristol-Myers Squibb shares in Q4 2023, an estimated $56.2M.
Invenomic Capital Management first reported a position in Bristol-Myers Squibb in Q1 2023 and held it in 3 quarters.
Invenomic Capital Management's Bristol-Myers Squibb position peaked at $56.2M in Q3 2023.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Invenomic Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.